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1. Introduction 
Cancer of the uterine endometrium is the most common gynecologic malignancy diagnosed 
in women of the United States. It is estimated that in 2011, there will be 46,470 new 
endometrial cancers and 8,120 deaths due to this malignancy (American Cancer Society, 
2011). The lifetime risk of developing endometrial cancer is approximately 3% in the general 
population. In Western countries, lifestyle changes and environmental factors play an 
important role in the carcinogenesis of endometrial cancer; however, there exist a 
proportion of cases in which an inherited predisposition increases this risk. In this chapter, 
hereditary nonpolyposis colorectal cancer syndrome or more commonly, Lynch Syndrome, 
will be reviewed and its association with endometrial cancer detailed. 
2. Lynch syndrome: Definition and clinical features 
Lynch syndrome (LS) or hereditary nonpolyposis colorectal cancer (HNPCC) is an 
autosomal-dominant hereditary cancer syndrome that predisposes carriers to multiple 
malignancies. It is caused by germline mutations in specific genes that participate in DNA 
mismatch repair (MMR), these include MLH1, MSH2, MSH6, PMS2, and most recently, 
EPCAM (Kupier et al., 2011; Lynch et al., 2003). As the name implies, colorectal cancer (CRC) 
traditionally has been perceived as the dominant malignancy with a lifetime risk of 43-48% 
for carriers, however, women with LS have an equal or greater lifetime risk of endometrial 
cancer (EC) (Stoffel et al., 2009). Further, in more than half of cases, women present with a 
gynecological cancer as their first or “sentinel” malignancy (Lu et al., 2005). For LS families, 
extracolonic cancers also include ovarian, stomach, upper urologic tract, small bowel, 
pancreas, hepato-biliary, brain (Turcot variant) and sebaceous adenomas/carcinomas (Muir-
Torre variant) (Lynch et al., 2003). This predisposition for other cancers has led to the use of 
Lynch Syndrome instead of HNPCC. It is also important to distinguish between Lynch I, in 
which colon cancer is the only contracted cancer, from Lynch II, where there exists other 
extracolonic cancers in the familial syndrome. In addition, some authors have reported a 
Lynch III as an appropriate name for identifying individuals with constitutively 
compromised MMR associated with biallelic mutations as seen with the Turcot and Muir-
Torre variants (Felton et al., 2007). 
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2.1 Clinical characteristics 
Current population estimates are that approximately 1 in 300 to 1 in 500 people carry a LS 
mutation making it similar in prevalence to Hereditary Breast and Ovarian cancer syndrome 
(Antoniou et al., 2000). These MMR mutations are inherited in an autosomal dominant 
manner and first-degree relatives have a 50% chance of inheriting the LS-related cancers 
(Hampel et al., 2005). Women who inherit LS-associated germline mutations have a greatly 
increased risk of developing a gynecologic cancer. Further, among women with LS who 
develop two primary cancers, over 50% are diagnosed with a gynecologic cancer before 
colon cancer (Lu et al., 2005). The range of risk for EC in women with LS is 27-71% 
compared with 3% in the general population and this risk varies with the specific MMR 
gene(s) involved, which will be discussed below (Koornstra et al., 2009).  
The suspicion of a LS mutation should be raised among women diagnosed with EC at 
younger ages. The mean age range of EC in women with LS is 46 to 54 years, compared to 60 
years in sporadic EC (Boks et al., 2002; Hampel et al., 2006). In a study by Lu et al., of 100 
women with EC under age 50, 9 (9%) were found to have identifiable mutations in the MMR 
genes MLH1, MSH2 and MSH6 (Lu et al., 2007). In another study that included 69 women 
with LS, EC was diagnosed under the age 40 in 18% of their cohort (Schmeler et al., 2006).  
Currently, there is no evidence to suggest that LS-associated EC portends a better or worse 
prognosis in patients when compared to sporadic EC. In fact, the majority of LS endometrial 
cancers are diagnosed in early stages, and like their sporadic counterparts, carry a favorable 
prognosis (Boks et al., 2002; Vasen et al., 1994). A case-control study of 50 women with LS-
associated EC matched to 100 controls with sporadic EC for age and stage, found similar 5-
year cumulative survival rates, 88% vs. 82%, respectively (P=0.59) (Boks et al., 2002). In 
another series of 125 women with clinically defined HNPCC, the overall survival rate for 
patients diagnosed with EC was high, with only 12% of patients succumbing to their disease 
(Vasen et al., 1994). A large study comparing the pathological features of sporadic EC to that 
of 50 patients with LS found that 78% were diagnosed as stage I, 10% were stage II, and 12% 
were stage III/IV in the LS cohort. Deep myometrial involvement was noted in 26% of cases, 
while lymphvascular space involvement was seen in 24%. However, when the LS cases were 
compared to the sporadic EC cases, stage, myometrial invasion, and lymphvascular space 
involvement were not statistically significantly different (Broaddus et al., 2006). 
2.2 Histopathologic characteristics 
Like sporadic endometrial cancer, the majority of LS-associated histology is of the 
endometrioid variety. However, studies evaluating the histologies of endometrial tumors in 
patients with LS have reported a wide variety of non-endometrioid types, including 
papillary serous carcinoma, clear cell carcinoma, malignant mixed Mullerian and 
neuroendocrine tumors (Broaddus et al., 2006; Carcangiu et al., 2010). For example, a small 
study of six LS-related endometrial cancers found significantly more often, poorly 
differentiated (83% versus 27%), presence of a Crohn-like lymphoid reaction (100% versus 
13%), lymphangio-invasive growth (67% versus 0%), and high number of tumor-infiltrating 
lymphocytes (100% versus 36%), when compared with sporadic ECs (van den Bos et al., 
2004). As mentioned previously, there is no evidence of a significant survival advantage or 
disadvantage associated with LS-related endometrial cancer (Boks et al., 2002). 
Conversely, tumor location appears to differ between sporadic and LS-associated 
endometrial cancer. Although the majority is commonly found in the uterine corpus, 
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endometrial cancer in the lower uterine segment (LUS) appears to have a strong association 
with Lynch syndrome. One study that included over 1000 patients with EC, found the 
prevalence of LS in patients with LUS tumors (10 of 35 or 29%) to be much greater than that 
of the general EC patient population (Westin et al., 2008). On the basis of this finding, the 
authors recommend that LS should be considered in all women with LUS tumors. 
3. Lynch syndrome: Mechanisms of carcinogenesis  
Six variants of the mismatch repair gene (MMR) have been cloned: MSH2 (MutS homolog 2, 
chromosome 2p16), MLH1 (MutL homolog 1, chromosome 3p21), MSH3 (MutS homolog 3, 
interacts with MLH1), MSH6 (MutS homolog 6, chromosome 2p16), PMS1 (postmeiotic 
segregation 1, chromosome 2q31) and PMS2 (postmeiotic segregation 2, chromosome 7p22) 
(Koessler et al., 2008). However, germline mutation analysis in four of these DNA-MMR genes 
(MLH1, MSH2, MSH6, and PMS2) is confirmatory diagnosis for LS (Hampel et al., 2005). A 
fifth and most recently identified gene, EPCAM (previously TACSTD1), is not a mismatch 
repair gene; however, large deletions in the 3’ end in the upstream EPCAM gene affect MSH2. 
This occurs by transcriptional read-through into and subsequent epigenetic silencing of its 
downstream neighbor, MSH2, resulting in the LS phenotype (Ligtenberg et al., 2009). 
The role of the MMR machinery is to maintain genomic integrity by correcting base-pair and 
small insertion-deletion mismatches that are generated during DNA replication. Two 
heterodimeric protein complexes, MutS-α and MutS-ȕ, recognize the mismatch. MutS-α is a 
heterodimer of MSH2 and MSH6 proteins and MutS-ȕ is an MSH2/MSH3 heterodimer, see 
Figure 1 (Masuda et al., 2011). Either MutS-α and MutS-ȕ heterodimers can recognize 
insertion/deletion loops with more than two bases, but MutS-α preferentially recognizes 
single base-pair mismatches or, one or two base pair insertion-deletion loops (Koessler et al., 
2008). The repair components of the MMR machinery involve three other heterodimer pairs: 
MutL-α (MLH1/PMS2), MutL-ȕ (MLH1/PMS1), and MutL-Ȗ (MLH1/MLH3). 
 
 
(Reproduced from Masuda et al., 2011). 
Fig. 1. The DNA Mismatch Repair (MMR) machinery in humans. 
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In general, affected patients with LS carry a germline mutation in one allele of a MMR gene 
and acquire a second mutation within the tumor. Common mechanisms of the “second hit” 
include allele inactivation by mutation, loss of heterozygosity, or promoter 
hypermethylation leading to epigenetic silencing. Biallelic inactivation of MMR genes 
results in genomic instability due to failure in the repair of base pair mismatches that 
occur commonly during DNA replication (approximately 1 in 106 base pairs). DNA 
mismatches commonly occur in regions of tandem repeats of short DNA sequences called 
microsatellites that make up about 3% of human DNA (Baudhuin et al., 2005). Normally, 
the MMR machinery corrects errors in microsatellites, but mutations in the MMR genes in 
tumors cause expansion or contraction of these regions compared to normal tissue. These 
genetic alterations in microsatellite length are termed “microsatellite instability” (MSI) 
and are the molecular signature of LS-associated cancers (Lynch et al., 2009). Further, the 
increased mutation rate that results from MMR loss leads to alterations in nucleotide 
repeats in many other pathways; those that control cell growth, regulate cell death, and in 
the MMR genes themselves. Together, this accumulation of mutations drives the 
carcinogenetic process in LS. 
3.1 MMR genes and the risk of endometrial cancer 
The range of cancer risks in LS varies depending on the MMR gene involved. 
Approximately 70-80% of the clinical features of LS are accounted for by MLH1 and MSH2 
mutations. Families with MSH6 and PMS2 mutations appear to have an attenuated cancer 
phenotype, presenting with a later age of diagnosis and a lower penetrance than MLH1 and 
MSH2. MSH6 may account for up to 15% and PMS2 for up to 3-15% of all identified LS 
mutations (Hampel et al., 2005; Niessen et al., 2009). Recently, EPCAM has been thought to 
account for approximately 1-3% of LS mutations (Kuiper et al., 2011).  
Endometrial cancer risk per MMR gene is as follows:  
MLH1 and MSH2: Endometrial cancer in patients with MLH1 and MSH2 mutations often 
occur before the age of 50. The risk in MLH1 and MSH2 carriers is up to 20% by age 50 and 
up to 60% by age 70 according to some studies (Aarnio et al., 1999; Lynch et al., 2009). 
However, the diagnosis of EC after the age of 50 should still raise concern for LS if there is a 
positive family history. 
MSH6: MSH6 mutation carriers appear to have the highest risk for endometrial cancer (up 
to 71%) of the MMR genes, higher than that of colorectal cancer (CRC) (Hendricks et al., 
2004). The average age of onset of EC in MSH6 mutation-positive individuals is 54 years. 
One study identified a somewhat lower risk for endometrial cancer in MSH6 mutation 
carriers, however the risk was significantly increased above the general population, and 
appeared to be higher than the risk for CRC in women with LS. They reported a risk for 
endometrial cancer to age 70 of 26% (95% CI: 18-36%) and risk to age 80 of 44% (95% CI: 30-
58%) (Baglietto et al., 2009). These reports suggest that if a woman carries an MLH1, MSH2 
or MSH6 mutation, her risk of EC may be even higher than her risk of CRC. 
PMS2: One large series of PMS2 carriers found the incidence of EC to be 7.5-fold higher than 
expected in the general population. This translates to a 15% risk to age 70 (Senter et al., 
2008).  
EPCAM: The clinical features of EPCAM/TACSTD1 mutations as a cause of Lynch 
syndrome is still being defined. Recent studies evaluating EPCAM 3’-end mutation carriers 
for their clinical phenotype found the risk for EC was dependent upon the type and size of 
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EPCAM mutation (Kempers et al., 2011; Kupier et al., 2011). However, since deletions in 
EPCAM lead to disruption of the MSH2 gene, following management guidelines for LS 
appears prudent at this point. Further research is needed to clarify the EC risks associated 
with EPCAM mutations and their association with LS. 
3.2 Microsatellite instability 
As discussed above, microsatellite instability (MSI) results from defects in the MMR 
machinery that correct the replication errors found in these regions of the human genome. 
MSI may occur via two mechanisms. MSI in the majority of EC is sporadic in nature, 
resulting from hypermethylation of the MLH1 promoter leading to epigenetic silencing of 
the gene (Esteller et al., 1998). The second, and the one associated with LS, is a consequence 
of germline mutations in the DNA-MMR genes as discussed above. Thus, MSI is not 
pathognomonic of LS, and in fact, LS accounts for only a minority of MSI-high EC cases 
(Meyer et al., 2009). 
MSI analysis may be performed on paraffin-embedded tissue sections. Amplification by 
PCR using five primers recommended by the National Cancer Institute-two mononucleotide 
(BAT25, BAT26) and three dinucleotide repeats (D2S123, D5S346, D173250)-are used to 
detect changes in the number of microsatellite repeats in tumor compared with normal 
tissue (Boland et al., 1998). Tumors are classified using the five marker panel as follows: 
MSI-high (MSI-H, highly unstable) if two or more of the five markers are positive, MSI-low 
(MSI-L, low instability) if one of the markers is positive, and MS-stable (MS-S, no instability) 
if none of the markers show MSI. MSI analysis has some limitations when used to detect LS-
associated endometrial cancers. Many, but not all the ECs that are diagnosed in LS are MSI-
H, while most, but not all MSI-H endometrial cancers are sporadic (Garg & Soslow, 2009). 
Thus, MSI analysis may fail to detect some LS-associated ECs, while it may turn out positive 
in a large percentage of sporadic ECs. 
3.3 Immunohistochemistry 
Mutations in the MMR genes typically result in truncated or absent protein products. 
Immunohistochemistry (IHC) staining using antibodies to the C-terminus of the MMR 
proteins can be used to identify LS-associated tumors for the absence of these gene products 
(Weissman et al., 2011). Like CRC, IHC in endometrial cancer has shown efficacy for 
identification of LS. However, results must be interpreted with caution since both absent 
MMR gene product and MLH1 promoter hypermethylation are found in up to one-third of 
endometrioid adenocarcinomas (Modica et al., 2007).  
Further, more than one gene product may be absent. This may be due to the 
heterodimerization of the MMR proteins. Thus, a loss in MLH1 staining is almost always 
coupled with concurrent loss of PMS2, and loss of MSH2 staining is accompanied by loss of 
MSH6. A deleterious mutation in either primary proteins MLH1 and MSH2 will most likely 
result in loss of the entire heterodimer (Wei et al., 2002). As an example, a lack of tumor 
staining for MLH1 and PMS2 is most likely the result of MLH1 protein absence. In contrast, 
PMS2 and MSH6 are secondary proteins, and a deleterious mutation in either gene will 
result in loss of that isolated protein. In addition, large deletions in the upstream EPCAM 
gene can cause inactivation and absence of MSH2 expression by IHC. As many as 20-25% of 
cases suspected of having a mutation in MSH2, are actually caused by germline deletions in 
EPCAM (Rumilla et al., 2011) 
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Assays to detect methylation of the MLH1 promoter that can recognize epigenetic 
mechanisms that lead to MSI-H, should be considered along with IHC for MMR gene 
testing (Whelan et al., 2002). For example, studies have shown that methylation of the small 
proximal region in the MLH1 promoter located -248 to -178 relative to the gene transcription 
start site invariably correlates with loss of MLH1 expression (Kang et al., 2002). If 
methylation is present, the patient most likely has sporadic tumor rather than LS-associated 
carcinoma. 
IHC has been shown to be a convenient and readily performed test for the detection of 
germline MMR gene mutations. There are, however, studies of mutations in the MMR genes 
that are not detected by IHC (Vasen et al., 2004). In fact, by most reports, there is an 
approximate 5-10 % false negative rate with both IHC and MSI. That is, up to 90-95% of 
CRCs and ECs seen in LS patients are MSI-H or lack at least one MMR protein product on 
IHC testing (Ferreira et al., 2009). Therefore, most experts recommend that IHC and MSI 
testing in combination, along with family and personal history, be used to maximize 
identification of patients at risk for LS so that germline genetic testing may confirm the 
diagnosis. 
4. Identifying patients at risk for Lynch syndrome 
In 1991, the International Collaborative Group on Hereditary Nonpolyposis Colorectal 
Cancer established research criteria, which became known as the Amsterdam Criteria (AC 
I), for the diagnosis of LS (Vasen et al., 1991). These criteria were broadened in 1999 as the 
Amsterdam Criteria II (AC II) to recognize a diagnostic role for extra-colonic tumors and 
suggested that LS-associated cancers should be suspected in relatives (Vasen et al., 1999) 
(see Table 1). 
 
AC I 
At least 3 relatives with histologically verified colorectal cancer (CRC): 
One is a first-degree relative of the other 2; 
At least 2 successive generations affected; 
At least 1 of the with CRC diagnosed at <50 years of age; 
Familial adenomatous polyposis (FAP) should be excluded. 
AC II 
At least 3 relatives must have a cancer associated with Lynch Syndrome 
(CRC, EC, stomach, ovary, ureter, renal pelvis, brain, small bowel, hepato- 
biliary, sebaceous tumors): 
One is a first-degree relative of the other 2; 
At least 2 successive generations affected 
At least 1 of the LS-associated cancers diagnosed at <50 years of age; 
FAP should be excluded in any CRC cases; 
Tumors should be verified whenever possible. 
(adapted from Vasen et al., 1991 & Vasen et al., 1999). 
Table 1. Amsterdam Criteria I and II. 
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Individuals meeting the AC I were presumptively defined as having LS. However, once MSI 
analyses and genetic testing became available, it became clear that certain families who met 
AC II criteria did not have an identifiable MMR germline mutation (Lindor et al., 2005). In 
fact, approximately half of patients with LS will be missed by these criteria and 
approximately half will meet the criteria and not have LS ie., do not carry MSI or MMR 
variations; but a high familial risk of uncertain etiology. The term “familial colorectal cancer 
type X” has been suggested for these patients to distinguish them from those with LS 
(Lindor et al., 2005). 
As a result of this major limitation of the AC, the Bethesda Guidelines were originally 
developed (1997) and revised (2004) to help identify patients with CRC or other LS-
associated cancers who should be screened for MSI (Umar et al., 2004). If found to have 
microsatellite unstable cancers, these patients should undergo subsequent germline MMR 
genetic testing (see Table 2).  
 
Tumors from individuals should be tested for MSI if: 
CRC1 diagnosed in a patient who is <50 years of age; 
Presence of synchronous, or metachronous LS-associated tumors2, regardless of age; 
CRC with MSI-H histology3 diagnosed in a patient who is <60 years of age; 
CRC diagnosed in a patient with 1 or more first-degree relatives with an LS-
associated cancer2, with one of the cancers being diagnosed under 50 years of age; 
CRC diagnosed in a patient with 2 or more first- or second-degree relatives with 
LS-associated cancers2 regardless of age.  
(adapted from Umar et al., 2004 and NCCN Guidelines Version 2.2011). 
1 Endometrial cancer <50 years of age is not included in the guidelines, however, current evidence 
suggests that these individuals should be evaluated for LS. 
2 LS-associated cancers include: CRC, EC, stomach, ovarian, ureter/renal pelvis, pancreas, hepatobiliary 
tract, brain (glioblastomas as seen in Turcot syndrome), small bowel, sebaceous adenomas and 
keratoacanthomas (seen in Muir-Torre syndrome). 
3 Presence of tumor infiltrating lymphocytes, Crohn’s-like lymphocytic reaction, mucinous (signet-ring) 
differentiation, or medullary growth pattern. 
Table 2. Revised Bethesda Guidelines. 
Despite the revised Bethesda criteria, multiple studies show the guidelines have low 
specificity, with approximately 80% of individuals who meet the criteria will not have LS 
(Hampel et al., 2005, 2006). Concerns that both the AC and Bethesda guidelines may miss a 
substantial portion of patients with LS, most investigators agree that all CRC cases be 
screened for MSI and that any case identified as MSI-H and/or show absence of ≥1 MMR 
protein, undergo further genetic testing for LS (EGAPP recommendations, 2009). Further, 
even with normal MSI and IHC, it is important to consider both the patient and their family 
history when determining to proceed with germline testing for LS. 
While it appears that these guidelines focus on CRC patients, it is important to know that 
they are at high risk of developing a synchronous or metachronous cancers, especially of the 
colon, rectum, endometrium and/or ovary (Lu et al., 2005; Lynch et al., 1977; Mecklin & 
Jarvinen, 1986; Watson et al., 2001). An early study found that among 33 families with 
“cancer family syndrome”, the risk of a second LS-associated cancer was approximately 30% 
within 10 years of the initial cancer diagnosis and up to 50% within 15 years of the initial 
cancer diagnosis (Mecklin & Jarvinen, 1986). Another report found the annual metachronous 
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CRC rates to be 2.1% and 1.7% between MLH1 and MSH2 families, respectively, as 
compared to 0.33% for the general population (Lin et al., 1998). In a study by Lu et al., dual 
primary cancers (CRC and gynecologic-endometrial or ovarian) were reported in 16 women 
(14%) of 117 women with LS (Lu et al, 2005). An earlier study found synchronous and 
metachronous cancers: endometrial (21 patients), CRC (28 patients), and either gastric, small 
bowel, or urinary tract cancers (6 patients), in 80 women with LS-associated ovarian cancer 
(Watson et al., 2001). 
The Society of Gynecologic Oncologists Education Committee published guidelines to 
identify women with a personal or family history of EC or ovarian cancer, and synchronous 
or metachronous CRC, whom may benefit from genetic risk assessment for LS (Lancaster et 
al., 2007) (see Table 3). 
 
Genetic risk assessment RECOMMENDED: 
Patients with >20-25% chance of  
having LS 
Genetic risk assessment may be HELFUL: 
Patients with >5-10% chance of 
having LS 
EC or ovarian cancer with a synchronous or 
metachronous CRC with the first cancer 
diagnosed < age 50; 
EC or ovarian cancer with synchronous or 
metachronous CRC or other LS-associated 
cancers* with the first cancer diagnosed at 
any age; 
EC or CRC and meet AC II criteria; EC or CRC diagnosed < age 50; 
First or second-degree relative with a known 
germline mutation in a MMR gene. 
EC or CRC with 2 or more first or second-
degree relatives with LS-associated 
cancers*; 
 
First or second-degree relative that meets 
the above criteria. 
(adapted from Lancaster et al., 2007). 
* LS-associated cancers include: CRC, EC, stomach, ovarian, ureter/renal pelvis, pancreas, hepatobiliary 
tract, brain (glioblastomas as seen in Turcot syndrome), small bowel, sebaceous adenomas and 
keratoacanthomas (seen in Muir-Torre syndrome). 
Table 3. Society of Gynecologic Oncologist: Guidelines for Lynch Syndrome Risk 
Assessment. 
5. Managing Lynch syndrome cancer risks 
Any discussion with individuals and family members at risk for hereditary cancer must occur 
in the context of a high risk cancer clinic with available medical interventions or referral made 
to address these risks. The benefits and limitations of surveillance and risk reducing surgery 
should be individualized, and when possible, evidence based. Over the past few years, a 
number of studies and recommendations have been published that document the available 
strategies to guide management of these at-risk individuals with LS (Lindor et al., 2006; NCCN 
Practice Guidelines 2011; Schmeler et al., 2006; Winawer et al., 2003). 
5.1 Surveillance 
Both EC and ovarian cancer are likely to develop before the menopause in women 
diagnosed with LS. Endometrial cancer screening in women with LS who are asymptomatic 
consists of annual endometrial sampling beginning at age 30 to 35 or five to ten years prior 
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to the earliest age of the family member diagnosed with a LS-associated cancer (Lindor et 
al., 2006; NCCN Practice Guidelines 2011). A recent Finnish study evaluated the efficacy of 
screening with endometrial biopsy and transvaginal ultrasound (TVUS) among 175 
mutation-positive women age 35 or older with LS (Renkonen-Sinisalo et al., 2007). They 
found that surveillance intrauterine biopsy detected 8 women with EC and 4 ECs were 
indicated by TVUS. Although no statistically significant differences were observed in cancer 
stage or survival when compared with 83 women with EC who did not undergo 
surveillance, this strategy detected earlier cancers and there were no deaths in the 
surveillance group.  
Studies have shown that endometrial thickness measurement to detect EC has a high false-
positive rate in women with LS, and in particular premenopausal women where 
endometrial thickness is highly variable (Dove-Edwin et al., 2002). Conversely, in 
postmenopausal women, atypical endometrial thickness is less variable. In this population, 
TVUS and endometrial sampling have similar sensitivities, and early detection is common 
because most women present with abnormal uterine bleeding (Dijkhuizen et al., 2000). 
The primary role of TVUS appears to be in ovarian cancer screening in women with LS. LS 
is associated with an increased risk of ovarian cancer, estimated at 12% by age 70 compared 
with 1.5% in the general population (Barrow et al., 2009). Although there are no data 
regarding ovarian cancer screening in women with LS, most experts recommend an annual 
pelvic exam, TVUS, and CA125 serum tumor marker, every 6 to 12 months, starting at age 
30 to 35 or five to ten years prior to the earliest age of the family member diagnosed with a 
LS-associated cancer (Lindor et al., 2006; NCCN Practice Guidelines 2011). Since ovarian 
cancer is much less common than EC in women with LS, it is unknown whether these 
screening strategies decrease morbidity and mortality.  
Although not the emphasis of this chapter, CRC surveillance recommendations in 
individuals with LS include, colonscopy every one to two years, beginning at age 20 to 25 or 
two to five years prior to the earliest diagnosis if it is before age 25 (Lindor et al, 2006; 
NCCN Practice Guidelines 2011). For MSH6 and PMS2 mutation positive carriers, 
colonoscopy is recommended at age 30 to 35 or 10 years prior to the youngest age of 
diagnosis in the family, whichever comes first (NCCN Practice Guidelines 2011; Senter et al., 
2008). In support of this strategy, one study showed that colonoscopy every 3 years reduced 
the CRC risk by 50% and decreased overall mortality by about 65% (Jarvinen et al., 2000). In 
a further study, the cumulative risk of CRC after a 10-year follow-up was 6% with a 
surveillance interval of 1-2 years compared to a 2-3 year surveillance (Vasen et al., 2010).  
Lynch syndrome is associated with an increased risk for other cancers as well, including, 
gastric, small bowel, urothelial, pancreatic, and brain. It is imperative that the clinician 
caring for these individuals and their families with LS, refer to the National Comprehensive 
Cancer Network (NCCN) Guidelines for management options for these cancer risks. 
5.2 Risk reducing surgery 
Women with LS may consider prophylactic hysterectomy and bilateral salpino-
oophorectomy (BSO) to substantially reduce the risk of endometrial and ovarian cancers 
(Guillem et al., 2006; NCCN Practice Guidelines 2011). In a large retrospective case-control 
study of 315 mutation-positive (MLH1, MSH2, or MSH6) women, risk-reducing 
hysterectomy with BSO proved to be an effective strategy for preventing endometrial and 
ovarian cancer (Schmeler et al., 2006). No women who had a hysterectomy developed EC 
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compared with 69 of 210 (33%) of the controls (no hysterectomy). Further, no women who 
underwent a BSO developed ovarian cancer compared with 12 of 233 (5%) of the controls 
(no BSO). One ovarian cancer was diagnosed in a woman who underwent a hysterectomy. 
Risk-reducing surgery may take place at the time of CRC diagnosis or once child-bearing is 
completed. In addition, there are no recommendations for chemopreventive strategies in LS 
to decrease gynecologic cancer risks. Studies from Lu et al., suggest oral contraceptive pills 
or medroxyprogesterone acetate (Depo-Provera) may have the potential to prevent EC 
and/or ovarian cancer associated with LS (Lu et al., 2010). 
Counseling regarding prophylactic surgery of this kind should include not only the risks 
inherent in surgery, but also premature menopause and its associated risks; menopausal 
vasomotor symptoms, estrogen therapy, osteoporosis, urogenital atrophy, and less clear, 
heart disease (Chen et al., 2007; Schmeler et al., 2006). Preoperative assessment should 
include colonoscopy, endometrial sampling, TVUS and a CA125 tumor marker. Preparation 
for a complete surgical staging should be available if occult carcinoma is found.  
Cost-effectiveness decisions must be reviewed with the patient when embarking on a 
management strategy for surveillance or prevention of LS-associated cancers. One study 
compared different strategies in a hypothetical cohort of women with LS: 1) no prevention, 
2) prophylactic hysterectomy and BSO at age 30, 3) prophylactic surgery at age 40, 4) annual 
screening with endometrial biopsy, TVUS and CA125 from age 30, and 5) annual screening 
from age 30 until prophylactic surgery at age 40 (combined strategy) (Kwon et al., 2008). The 
authors found that annual screening followed by prophylactic surgery at age 40 was the 
most effective gynecologic cancer prevention strategy, but the incremental benefit over risk-
reducing surgery alone came with a substantial cost. Thus, a careful review of different 
strategies to improve the effectiveness and decrease the lifetime costs of these interventions 
is warranted in patients with LS. 
6. Conclusion 
Lynch Syndrome (hereditary nonpolyposis colorectal cancer ) is an autosomal dominant 
disorder that is caused by germline mutations in one of several DNA-MMR genes (MLH1, 
MSH2, MSH6, PMS2, and EPCAM). The syndrome is characterized by an approximate 
lifetime risk of EC and CRC of 40% to 60% in affected individuals. Other LS-associated cancers 
(gastric, ovarian, urothelial, pancreas, hepatobiliary tract, brain, small bowel, skin) as well as, 
synchronous and metachronous cancers, may present in these patients and their families. 
Identification of these individuals meeting AC II and/or Bethesda guidelines should have 
their tumors tested for MSI and for MMR protein expression by IHC. Further genetic 
counseling and direct MMR gene testing of those at-risk individuals should be done in the 
context of an established high risk genetics/cancer clinic. Post-test genetic counseling 
regarding the risks and benefits of LS-associated cancer surveillance and prophylactic surgery 
strategies, should be performed with consideration of the informed consent, completed child-
bearing, autonomy, cost-effectiveness and quality of life, for each individual patient. 
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